Biocept (NASDAQ:BIOC) was downgraded by investment analysts at ValuEngine from a “buy” rating to a “hold” rating in a research report issued on Monday, February 4th.
Separately, Zacks Investment Research lowered Biocept from a “hold” rating to a “sell” rating in a research report on Tuesday, December 25th.
Shares of BIOC traded up $0.02 during midday trading on Monday, reaching $1.05. The stock had a trading volume of 474,954 shares, compared to its average volume of 2,256,230. The stock has a market capitalization of $2.27 million, a P/E ratio of -0.04 and a beta of 3.09. Biocept has a 12-month low of $0.66 and a 12-month high of $12.30. The company has a current ratio of 2.63, a quick ratio of 2.50 and a debt-to-equity ratio of 0.11.
A hedge fund recently raised its stake in Biocept stock. Dimensional Fund Advisors LP raised its holdings in shares of Biocept Inc (NASDAQ:BIOC) by 180.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 110,500 shares of the medical research company’s stock after purchasing an additional 71,055 shares during the period. Dimensional Fund Advisors LP owned 4.86% of Biocept worth $95,000 at the end of the most recent reporting period. 10.47% of the stock is owned by hedge funds and other institutional investors.
Biocept, Inc, an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms.
Further Reading: Moving Average – How it Helps Investors in Stock Selection
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with MarketBeat.com's FREE daily email newsletter.